Revelation Biosciences, Inc. (REVB) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Revelation Biosciences is implementing automated screening systems and software for processing large clinical datasets. The business relies on synergy with academic centers to develop agents that activate the body's natural defenses. This EV/EBITDA chart, with a value of 0.00, reflects the dynamics of a company whose success depends on the efficacy of candidate molecules in combating sepsis and severe infections.
revbiosciences.com - analytical breakdowns and key metrics (REVB)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
Debt to Equity Revelation Biosciences|REVB - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Revelation Biosciences, Inc.|REVB - Company Cumulative Debt|Debt to Book Capitalization Ratio Revelation Biosciences Corp|REVB - Company Long-Term Loans and Borrowings|Company Short-Term Debts Revelation Biosciences|Quick Liquidity Indicator revbiosciences.com
- business earnings and investment ratios data:
REVB - Company Net Income|Projected Future Earnings Revelation Biosciences|REVB - Market Cap to Earnings|Future Price to Earnings Revelation Biosciences|REVB - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Revelation Biosciences Corp|REVB - Operating profit EBITDA|Net earnings per share for the last 12 months Revelation Biosciences|REVB - Earnings per share for the last four quarters|Quarterly EPS earnings growth revbiosciences.com|REVB - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Revelation Biosciences
Initial company analysis:REVB (Revelation Bio)
The development of immunomodulators by Revelation Biosciences (REVB) requires significant expenditures, which is reflected in the company's EV/EBITDA ratio on the financial timeline. This metric, with a value of 0.00, correlates the total enterprise value with operating profit to measure debt service efficiency. A decrease in this ratio signals profit growth relative to capitalization, confirming the company's stability until the completion of critical clinical trials and FDA approval.
Key competitors
EV/EBITDA Multiple ARGX (Argenx)|Total Company Value to Operating Income Before Depreciation Ratio BioNTech Pharma (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|admabiologics.com (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant Inc|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple Grifols Biemat|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies (ADPT)|celldex.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (Aurinia Pharmaceuticals Inc.)|BioCryst Pharmaceuticals, Inc. (BCRX) - Company Value to EBITDA|VERA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation DNTH (Dianthus Corp)|PHVS: EV/EBITDA Multiple|Company Value to EBITDA AbCellera (ABCL)|Enterprise Value to EBITDA Ratio TRML|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PGEN|EV/EBITDA Multiple PHAR|NKTR - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Upstream Bio Inc UPB|zenasbio.com - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Immunome - EV/EBITDA Multiple|GOSS - EV/EBITDA Multiple|KALV (KalVista Pharmaceuticals Inc) - Enterprise Value to EBITDA Ratio|SEPN: Enterprise Value to Operating Income Before Depreciation Ratio|PVLA (Pieris Pharmaceuticals) - EV/EBITDA Multiple|savarapharma.com (SVRA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rigel Pharmaceuticals, Inc. (RIGL)|ANAB - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Astria Pharma ATXS|ENGN: Enterprise Value to Operating Income Before Depreciation|RAPT: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation JBIO (Aerovate Therapeutics Inc)|ACRS: EV/EBITDA Multiple|KYTX (Kyverna Therapeutics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TLSA (Tiziana Life Sciences PLC) - EV/EBITDA Multiple|Cabaletta Bio Inc (CABA) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ventyx Biosciences (VTYX)|THTX - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Avalo Therapeutics AVTX|Total Company Value to Operating Income Before Depreciation Ratio Eledon Pharmaceuticals Inc. (ELDN)|Agenus Inc - EV/EBITDA Multiple|Climb Bio, Inc (CLYM) - Enterprise Value to EBITDA Ratio|ZURA: EV/EBITDA Multiple|ATYR - Total Company Value to Operating Income Before Depreciation Ratio|ADAG (Adagene Inc) - EV/EBITDA Multiple|Company Value to EBITDA Ikena Oncology, Inc. IMA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Shattuck Labs, Inc. (STTK)|equilliumbio.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple CNTB (Connect Biopharma Holdings Limited)|IMUX - Enterprise Value to EBITDA Ratio|Atara Biotherapeutics Inc - EV/EBITDA Multiple|Company Value to EBITDA InflaRx N.V.|X4 Pharma (XFOR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACET - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Celularity Inc|INMB: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple BRNS|KZR - Company Value to EBITDA|SAB Biotherapeutics, Inc - Enterprise Value to EBITDA Ratio|Akari Therapeutics, Plc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enlivex Therapeutics, Ltd. - EV/EBITDA Multiple|QTTB: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|GeoVax (GOVX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio EDSA (Edesa Biotech Inc)|IBIO (iBio Corp) - EV/EBITDA Multiple|CARM: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple XTLB|EV/EBITDA Multiple boltbio.com (BOLT)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization HCW Biologics HCWB|Business Value to Operating Income Before Depreciation APVO|AIM - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Aditxt (ADTX) - Enterprise Value to EBITDA Ratio|GRI: EV/EBITDA Multiple|xortx.com (XRTX) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio HIND|INDP: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple SCNI|Total Company Value to Operating Income Before Depreciation Ratio calcimedica.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Affimed N.V. AFMD|ALLK - Enterprise Value to EBITDA Ratio|HOOK - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGM Biosciences, Inc. (IGMS) - Enterprise Value to EBITDA Ratio|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Ocean Biomedical Corp (OCEA) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC Biopharm|Enterprise Value to Operating Income Before Depreciation THRD (thirdharmonicbio.com)
